ArticleMolecular oncology2022
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Prognostic, Predictive, and Clinical Relevance of DNA Damage Repair Alterations in Biliary Tract Cancers.Cancers · 2026Review
- Emerging omics diagnosis of perihilar cholangiocarcinoma.Journal of gastroenterology · 2026Article
- Impact of MGMT methylation on overall survival in solid tumors: A systematic review and meta-analysis.Experimental and therapeutic medicine · 2026Article
- Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment.Biomolecules · 2025Review
- Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 5 institutions in 2 countries.
Monica NigerMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.ORCID 0000-0002-9055-5338
Federico NichettiMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Andrea Casadei-GardiniVita-Salute San Raffaele University, Milan, Italy.
Federica MoranoMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Chiara PircherMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Elena TamboriniPathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Federica PerronePathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Matteo CanaleBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy.ORCID 0000-0002-9768-7149
Daniel B LipkaSection Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT) Heidelberg, Germany.
Andrea VingianiPathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Luca AgnelliPathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Anna DobberkauSection Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT) Heidelberg, Germany.
Jennifer HülleinComputational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Felix KorellHeidelberg and Partner Sites, German Cancer Consortium (DKTK), Heidelberg, Germany.
Christoph E HeiligHeidelberg and Partner Sites, German Cancer Consortium (DKTK), Heidelberg, Germany.
Sara PuscedduMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Francesca CortiMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Michele DrozDivision of HPB, General Surgery and Liver Transplantation, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Italy.
Paola UliviBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy.
Michele PrisciandaroMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Maria AntistaMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Marta BiniMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Laura CattaneoPathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Massimo MilionePathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Hanno GlimmHeidelberg and Partner Sites, German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0003-4104-1135
Bruno C KöhlerHeidelberg and Partner Sites, German Cancer Consortium (DKTK), Heidelberg, Germany.
Giancarlo PruneriPathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Daniel HübschmannComputational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stefan FröhlingHeidelberg and Partner Sites, German Cancer Consortium (DKTK), Heidelberg, Germany.
Vincenzo MazzaferroDivision of HPB, General Surgery and Liver Transplantation, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Italy.
Filippo PietrantonioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Maria Di BartolomeoMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Filippo de BraudMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
Fondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Cancer Research Center · DEUniversity of Milan · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITVita-Salute San Raffaele University · IT
Funding
Cancer Research UK 29374
Abstract
Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O
Indexed as
Bile Duct NeoplasmsBiliary Tract NeoplasmsBiomarkersDNA Modification MethylasesDNA Repair EnzymesHumansO(6)-Methylguanine-DNA MethyltransferasePrecision MedicineTumor Suppressor ProteinsBiomarkersDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanO(6)-Methylguanine-DNA MethyltransferaseTumor Suppressor Proteinsbiliary tract cancerbiomarkercholangiocarcinomaMGMTmolecular profilingtemozolomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.